Abstract:Background: Monocytes and macrophages play an indispensable role in maintaining intestinal homeostasis and modulating mucosal immune responses in inflammatory bowel disease (IBD). Although numerous studies have described macrophage properties in IBD, the underlying mechanisms whereby the monocyte-macrophage lineage modulates intestinal homeostasis during gut inflammation remain elusive. Main body: In this review, we decipher the cellular and molecular mechanisms governing the generation of intestinal mucosal macrophages and fill the knowledge gap in understanding the origin, maturation, classification, and functions of mucosal macrophages in intestinal niches, particularly the phagocytosis and bactericidal effects involved in the elimination of cell debris and pathogens. We delineate macrophage-mediated immunoregulation in the context of producing pro-inflammatory and anti-inflammatory cytokines, chemokines, toxic mediators, and macrophage extracellular traps (METs), and participating in the modulation of epithelial cell proliferation, angiogenesis, and fibrosis in the intestine and its accessory tissues. Moreover, we emphasize that the maturation of intestinal macrophages is arrested at immature stage during IBD, and the deficiency of MCPIP1 involves in the process via ATF3-AP1S2 signature. In addition, we confirmed the origin potential of IL-1B+ macrophages and defined C1QB+ macrophages as mature macrophages. The interaction crosstalk between the intestine and the mesentery has been described in this review, and the expression of mesentery-derived SAA2 is upregulated during IBD, which contributes to immunoregulation of macrophage. Moreover, we also highlight IBD-related susceptibility genes (e.g., RUNX3, IL21R, GTF2I, and LILRB3) associated with the maturation and functions of macrophage, which provide promising therapeutic opportunities for treating human IBD. Conclusion: In summary, this review provides a comprehensive, comprehensive, in-depth and novel description of the characteristics and functions of macrophages in IBD, and highlights the important role of macrophages in the molecular and cellular process during IBD.

The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease

Advances in Macrophage-Targeting Nanoparticles for the Diagnosis and Treatment of Inflammatory Bowel Disease.

Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease

Involvement of Embryo-Derived and Monocyte-Derived Intestinal Macrophages in the Pathogenesis of Inflammatory Bowel Disease and Their Prospects as Therapeutic Targets

Dynamic role of macrophage CX3CR1 expression in inflammatory bowel disease

Cross-talk between macrophages and gut microbiota in inflammatory bowel disease: a dynamic interplay influencing pathogenesis and therapy

Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD

Macrophages in intestinal homeostasis and inflammatory bowel disease

Intestinal Macrophage Autophagy and its Pharmacological Application in Inflammatory Bowel Disease

Crosstalk between gut microbiota and gut resident macrophages in inflammatory bowel disease

Exosome-mediated Macrophage Regulation for Inflammatory Bowel Disease Repair: a Potential Target of Gut Inflammation.

Human Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease

Potential Role of Th17 Cells in the Pathogenesis of Inflammatory Bowel Disease.

Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease.

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Interplay of Intestinal Microbiota and Mucosal Immunity in Inflammatory Bowel Disease: a Relationship of Frenemies

Role of MicroRNAs in Regulating T Cell Responses in Inflammatory Bowel Disease

Targeting macrophage autophagy for inflammation resolution and tissue repair in inflammatory bowel disease

Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD

Current Status of M1 and M2 Macrophages Pathway as Drug Targets for Inflammatory Bowel Disease